Wang Xiaodong, Cederbaum Arthur I
Department of Pharmacology and Biological Chemistry, Mount Sinai School of Medicine, New York, NY 10029, USA.
J Pharmacol Exp Ther. 2006 Apr;317(1):44-52. doi: 10.1124/jpet.105.098004. Epub 2005 Dec 22.
S-Adenosyl-l-methionine (SAM) has been shown to be hepatoprotective against many toxic agents. Its possible effectiveness in protecting against CYP2E1-dependent toxicity is not known. We recently reported that treatment of mice with pyrazole to induce CYP2E1 increased hepatotoxicity produced by Fas agonistic Jo2 antibody. The current study was designed to investigate the effect of exogenous administration of SAM on the synergistic hepatotoxicity produced by Fas agonistic Jo2 antibody plus CYP2E1 following pyrazole pretreatment in C57BL/6 mice. Suboptimal administration of Jo2 Fas antibody combined with pyrazole pretreatment caused severe hepatotoxicity as determined by elevations in serum transaminase levels and histopathology. Exogenous administration of SAM (50 mg i.p./kg body weight every 12 h for 3 days) significantly decreased serum transaminases and ameliorated morphological changes of the liver. Addition of SAM elevated hepatic SAM and total reduced glutathione levels and inhibited CYP2E1 activity. SAM also lowered the elevated oxidative stress (lipid peroxidation, protein carbonyls, and superoxide production) and nitrosative stress (induction of inducible nitric-oxide synthase and 3-nitrotyrosine adducts) and increases in caspase-8 and -3 activation produced by the pyrazole plus Jo2 treatment. SAM did not prevent the increase in serum TNF-alpha levels or the decrease in catalase activity in this model. These results indicate that SAM can have an important hepatoprotective role as an effective reagent against Fas plus CYP2E1-induced hepatotoxicity by lowering oxidative and nitrosative stress.
S-腺苷-L-甲硫氨酸(SAM)已被证明对多种毒性物质具有肝保护作用。其在预防CYP2E1依赖性毒性方面的潜在有效性尚不清楚。我们最近报道,用吡唑处理小鼠以诱导CYP2E1会增加Fas激动性Jo2抗体产生的肝毒性。本研究旨在探讨外源性给予SAM对C57BL/6小鼠经吡唑预处理后Fas激动性Jo2抗体加CYP2E1产生的协同肝毒性的影响。次优剂量的Jo2 Fas抗体与吡唑预处理相结合导致严重肝毒性,这通过血清转氨酶水平升高和组织病理学得以确定。外源性给予SAM(每12小时腹腔注射50 mg/kg体重,共3天)显著降低了血清转氨酶水平,并改善了肝脏的形态学变化。添加SAM提高了肝脏SAM和总还原型谷胱甘肽水平,并抑制了CYP2E1活性。SAM还降低了吡唑加Jo2处理所产生的升高的氧化应激(脂质过氧化、蛋白质羰基化和超氧化物生成)和亚硝化应激(诱导型一氧化氮合酶和3-硝基酪氨酸加合物的诱导)以及caspase-8和-3激活的增加。在该模型中,SAM并未阻止血清TNF-α水平的升高或过氧化氢酶活性的降低。这些结果表明,SAM作为一种有效试剂,通过降低氧化应激和亚硝化应激,在对抗Fas加CYP2E1诱导的肝毒性方面可发挥重要的肝保护作用。